| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 41 | AT98949512 | 1998-09-24 | ATE297398T1 | 2005-06-15 | MOLLISON KARL W | |
| 42 | AT02014642 | 2002-07-02 | ATE259801T1 | 2004-03-15 | CZERNEY PETER DR; WENZEL MATTHIAS DR; FRANK WILHELM DR; LEHMANN FRANK DR | |
| 43 | AT02014642 | 2002-07-02 | AT259801T | 2004-03-15 | CZERNEY PETER DR; WENZEL MATTHIAS DR; FRANK WILHELM DR; LEHMANN FRANK DR | |
| 44 | HALO-ALKYL ESTERS OF CAMPTOTHECINS AND METHODS OF TREATING CANCER USING THESE COMPOUNDS | CA2484816 | 2003-04-22 | CA2484816A1 | 2003-11-20 | ZHISONG CAO; BEPPINO C GIOVANELLA |
| Halo-alkyl esters of camptothecin are described. Processes for making these compounds and for using them in cancer treatment, are also described. | ||||||
| 45 | CASCADE ESTERS OF CAMPTOTHECINS AND METHODS OF TREATING CANCER USING THESE COMPOUNDS | CA2484815 | 2003-04-22 | CA2484815A1 | 2003-11-20 | ZHISONG CAO; BEPPINO GIOVANELLA C |
| Cascade esters of camptothecin are described. Processes for making these compounds and for using them in cancer treatment are also described. | ||||||
| 46 | DERIVADOS DE RAPAMICINA QUE CONTIENE TETRAZOL CON VIDAS MEDIAS ACORTADAS Y SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO | ARP980104798 | 1998-09-25 | AR015940A1 | 2001-05-30 | |
| Análogo de rapamicina que tiene la formula (I) o una sal o prodroga del mismo farmacéuticamente aceptable que es un agente inmunomodulador y esutil en el tratamiento de restenosis, enfermedades inmunes y autoinmunes, e inhibe cáncer, desarrolofungal , y el rechazo a los tejidos de post-transplante;y su uso para la manufactura de un medicamento. | ||||||
| 47 | TETRAZOLE-CONTAINING RAPAMYCIN ANALOGS WITH SHORTENED HALF-LIVES | IL13460798 | 1998-09-24 | IL134607A0 | 2001-04-30 | |
| 48 | TETRAZOLECONTAINING ANALOGUES OF RAPAMYCIN, HAVING REDUCED PERIOD OF SEMIDECOMPOSITION | BG10431600 | 2000-04-07 | BG104316A | 2000-12-29 | MOLLISON KARL W |
| The compound with the formula or its pharmaceutically acceptable salt or precursor is an immunomodulation form and is useful for the treatment of restenosis and immune and autoimmune diseases. The invention is also related to compounds and a method for the inhibition of cancer, mycotic growth, restenosis, rejection after tissue transplants, as well as to compositions for the inhibition of immune and autoimmune diseases in mammals, with reduced to minimum side effects as a result of the reduced period of halfdecomposition. 8 claims, 1 figure | ||||||
| 49 | Rapamycin analogs containing tetrazol with shortened half-life | CZ20001014 | 1998-09-24 | CZ20001014A3 | 2000-07-12 | MOLLISON KARL W |
| 50 | NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | CA2324895 | 1999-03-17 | CA2324895A1 | 1999-09-30 | MEVELEC LAURENCE; ROBIN JEAN-PIERRE; GIRODIER LAURENT; DUJARDIN GILLES; FOURNIER FLORENCE; DHAL ROBERT; ROBIN JULIE; CAVOLEAU SYLVIE; GILET CHRYSTELLE; ROUAUD SYLVIE; POUTOT SANDRINE; CHAUVIAT LUDOVIC; CHARBONNEL SANDRA |
| The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alcaloïds used in chimiotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and fonctionalization are entirely preformed. | ||||||
| 51 | Tetrazole-containing rapamycin analogs with shortened half-lives | ZA988750 | 1998-09-23 | ZA988750B | 1999-04-01 | MOLLISON KARL W |
| 52 | Tetrazole-containing rapamycin analogs with shortened half-lives | ZA9808750 | 1998-09-23 | ZA9808750B | 1999-04-01 | MOLLISON KARL W |
| A compound having formula (I) or a pharmaceutically acceptable salt or prodrug thereof, is an immunomodulatory agent and is useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post- transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosis, post- transplant tissue rejection, and immune and autoimmune disease in a mammal, with minimized side-effects due to shortened half-lives. | ||||||
| 53 | THIOETHER COMPOUNDS FOR USE IN PREPARING BIFUNCTIONAL CHELATING AGENTS FOR THERAPEUTIC RADIOPHARMACEUTICALS | CA2188565 | 1995-04-25 | CA2188565A1 | 1995-11-09 | VOLKERT WYNN A; KETRING ALAN R; VENKATESH MEERA; SCHLEMPER ELMER; JURISSON SILVIA |
| A compound consisting essentially of a multidentade ligand including at least two thioether groups for being complexed to Rhodium-105 in specific activities that are sufficiently high for use in formulating therapeutic 105Rhradiopharmaceuticals. | ||||||
| 54 | PROCESS FOR PRODUCING THIQCYCLOALKENO(3,2-B)PYRIDINE DERIVATIVE INTERMEDIATES | HU488488 | 1987-04-08 | HU201942B | 1991-01-28 | SCHWENDER CHARLES F; DODD JOHN H |
| 55 | bicyclic sulfonamide | DK549086 | 1986-11-17 | DK549086A | 1987-05-19 | NARISADA MASAYUKI; OHTANI MITSUAKI; WATANABE FUMIHIKO; HAGISHITA SANJI; SENO KAORO; KAMATA SUSUMU; HAGA NOBUHIRO; TSURI TATSUO; TSUSHIMA TADAHIKO; KAWADA KENJI |
| 56 | TRIFLUOROMETHANESULFONANILIDE DERIVATIVES,THEIR PRODUCTION AND HERBICIDES CONTAINING THEM AS ACTIVE INGREDIENTS | EG48682 | 1982-08-09 | EG16122A | 1987-04-30 | HIROYUKI KONISHI |
| 57 | Process for preparing sulfur organic compounds | FR901102D | 1943-06-22 | FR901102A | 1945-07-18 | |
| 58 | Fenilni derivati kot agonisti kanabinoidnega receptorja 2 | SI201630724 | 2016-12-06 | SI3386951T1 | 2020-07-31 | GAVELLE OLIVIER; GRETHER UWE; NETTEKOVEN MATTHIAS; ROEVER STEPHAN; ROGERS-EVANS MARK; ROMBACH DIDIER |
| 59 | (PYRIDO/THIENO)-[F]-OXAZEPIN-5-ONE DERIVATIVES AS POSITIVE MODULATORS OF THE AMPA RECEPTOR | CA2449215 | 2002-06-10 | CA2449215C | 2011-03-22 | GROVE SIMON JAMES ANTHONY; ADAM-WORRALL JULIA; ZHANG MINGQIANG; GILFILLAN ROBERT |
| The present invention relates to (pyrido/thieno)-[f]-oxazepine-5-one derivatives having the general Formula (I) wherein R1, R2 and R3 are independently H or (C1-4)alkyl; Ar represents a fused thiophene or pyridine ring optionally substituted with one or more substituents selected from (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy(C1-4)alkyl, CF3, halogen, nitro, cyano, NR4R5, NR4COR6, and CONR4R5; R4 and R5 are independently H or (C1-4)-alkyl; or R4 and R5 form together with the nitrogen atom to which they are bound a 5-or 6-membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O, S or NR6; R6 is (C1-4)alkyl; A represents the residue of a 4-7 membered saturated heterocyclic ring, optionally containing an oxygen atom, the ring being optionally substituted with 1-3 substituents selected from (C1-4)alkyl, (C1-4)-alkyloxy, hydroxy, halogen and oxo; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of these (pyrido/thieno)-[f]-oxazepine-5-one derivatives in the treatment of neurological diseases and psychiatric disorders which are responsive to enhancement of synaptic responses mediated by AMPA receptors in the central nervous system. | ||||||
| 60 | (Pyrido/thieno)-[f]-oxazepin-5one derivatives, pharmaceutical composition containing thereof and their use | SK15262003 | 2002-06-10 | SK287583B6 | 2011-03-04 | GROVE SIMON JAMES ANTHONY; ADAM-WORRALL JULIA; ZHANG MINGQIANG; GILFILLAN ROBERT |
| Described are (pyrido/thieno)-[f]-oxazepin-5one derivatives of the general formula (I), wherein particular substituents have the meaning described in claims. Described are also pharmaceutical compositions containing thereof and their use for the treatment of neurological diseases and psychiatric disorders, which are responsive to enhancement of synaptic responses mediated by AMPA receptors in the central nervous system. | ||||||
QQ群二维码
意见反馈
意见反馈